Resonance Health Ltd (ASX: RHT) is pleased to announce the receipt of a $732,851 refund from the Australian Taxation Office, reflecting the net difference between the Research and Development tax incentive for FY2025 and income taxation payable. This refund bolsters our cash reserves, to be detailed in the upcoming March 2026 report.

As a healthcare technology company, Resonance Health offers vital services globally, with a focus on disease management and clinical trials. Our commitment to quality and innovation has led to regulatory approvals for a range of Software-as-Medical Devices, including FerriScan® and HepaFatScan®. We continue to develop new products, such as the MRI Liver Fibrosis Project, and expand our reach in clinical trials management.

For more information, visit our investor page at https://investors.resonancehealth.com. We welcome any questions you may have regarding this announcement and our ongoing operations. Stakeholders are encouraged to engage with us on LinkedIn and register their interest on our website.

Please note that the information presented may contain forward-looking statements and involve certain risks and uncertainties. We remain committed to transparency and regulatory compliance in all our endeavors.